|
CAPR | Capricor Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.09 |
| Leverage | 33.67% |
| Market Cap | $ 908.4m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -81.8m |
| Margin | -853.54% |
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.